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Abstract
Background—Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated
with clinically overt heart failure (HF). However, whether it provides additive prognostic
information for incident HF beyond traditional risk factors and left ventricular (LV) mass index
among multi-ethnic asymptomatic individuals has not yet been determined. We studied the
associations of plasma NT-proBNP and magnetic resonance imaging defined LV mass index with
incident HF in an asymptomatic multi-ethnic population.
Methods and Results—A total of 5597 multi-ethnic participants without clinically apparent
cardiovascular disease underwent baseline measurement of NT-proBNP and were followed for
5.5±1.1 years. Among them, 4163 also underwent baseline cardiac magnetic resonance imaging.
During follow-up, 111 participants experienced incident HF. Higher NT-proBNP was significantly
associated with incident HF, independent of baseline age, sex, ethnicity, systolic blood pressure,
diabetes mellitus, smoking, estimated glomerular filtration rate, medications (anti-hypertensive
and statin), LV mass index, and interim myocardial infarction (hazard ratio: 1.95 per 1U log NT-
proBNP increment, 95% CI 1.54–2.46, P<0.001). This relationship held among different ethnic
groups, non-Hispanic whites, African-Americans, and Hispanics. Most importantly, NT-proBNP
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provided additive prognostic value beyond both traditional risk factors and LV mass index for
predicting incident HF (integrated discrimination index=0.046, P<0.001; net reclassification
index; 6-year risk probability categorized by <3%, 3–10%, >10% =0.175, P=0.019; category-less
net reclassification index=0.561, P<0.001).
Conclusions—Plasma NT-proBNP provides incremental prognostic information beyond
traditional risk factors and the magnetic resonance imaging-determined LV mass index for
incident symptomatic HF in an asymptomatic multi-ethnic population.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier:
NCT00005487.
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Neurohormonal activation and left ventricular (LV) remodeling are important contributors to
progressive cardiac dysfunction and heart failure (HF).1 N-terminal pro-B-type natriuretic
peptide (NT-proBNP), as an index of neurohormonal activation, has been shown to be
associated with mortality and rehospitalization in patients with clinically overt HF.2
Moreover, recent studies have shown that the level of plasma NT-proBNP is associated with
risk of future HF in population-based studies.3,4 However, previous studies have not
addressed 2 important questions: (1) whether the predictive value of NT-proBNP is additive
beyond traditional HF risk factors and LV hypertrophy; and (2) whether NT-proBNP levels
predict HF across different ethnic groups of asymptomatic individuals. Plasma natriuretic
peptide level has been shown to be affected by several factors, including age, sex, and body
habitus. Moreover, there is controversy concerning ethnic difference in HF severity and NT-
proBNP levels.5 As previous population-based studies were mainly conducted in whites, the
applicability of their study results to multi-ethnic populations remains to be investigated.3 In
addition, a recent study showed that the predictive value of NT-proBNP for incident HF was
poor in healthy populations with structurally normal hearts,6 suggesting that NT-proBNP
may function as a risk factor by virtue of detecting advanced LV remodeling.
LV hypertrophy, which reflects LV remodeling, has also been shown to be a strong
predictor of incident HF in asymptomatic populations.7,8 However, it is unclear whether
there is an additive prognostic role for NT-proBNP beyond direct measurements of LV mass
in predicting incident HF in multiethnic populations without previous history of
cardiovascular disease. Therefore, a systematic approach to answer this question using LV
mass measured by cardiac magnetic resonance imaging (MRI), currently the most accurate
method, is needed. Improved understanding of the interplay between NT-proBNP and LV
mass for prognostic purposes could also provide unique pathophysiologic insight into how
these factors relate to the development of symptomatic HF.
Therefore, in this study, we sought to evaluate the predictive ability of NT-proBNP in
comparison with cardiac MRI-determined LV mass for incident symptomatic HF, in a large
multi-ethnic population comprising non-Hispanic whites, Chinese, Hispanics, and African-
Americans.
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Methods
Study Population
The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective study designed to
evaluate mechanisms underlying the development and progression of subclinical
cardiovascular diseases among asymptomatic individuals in the general population. Details
of the MESA study design have been previously described.9 In short, 6814 American men
and women, 45 to 84 years of age and of 4 self- reported ethnicities (non-Hispanic white,
African-American, Hispanic, and Chinese) who were free of known cardiovascular disease
and free of any history of HF were enrolled in 6 participating centers in the United States.
Upon entry, all participants underwent extensive evaluations, including questionnaires,
physical examination, and laboratory tests, subjects diagnosed with cardiovascular disease
or symptomatic HF were then excluded. Among the 6814, 5597 underwent plasma NT-
proBNP measurements, and the clinical characteristics of this subpopulation were very
similar to the entire MESA cohort. Among them, 4163 also underwent cardiac MRI.
Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure
≥90 mm Hg, or treatment for hypertension. Individuals with diabetes were defined as either
having fasting plasma glucose ≥126 mg/dL or receiving treatment for diabetes mellitus.
Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal
Disease equation.10
Plasma NT-proBNP Measurements
The plasma concentration of NT-proBNP was measured using a highly sensitive and
specific Elecsys electrochemiluminescence immunoassay based on the double-antibody
sandwich method (Roche Diagnostics Corporation, Indianapolis, IN). A 250 μl serum
sample previously unthawed or only thawed once was used for analysis. All analyses were
performed at the core-lab ((University of California, San Diego)) and the intra-and
interassay coefficients of variation were as follows: at 175 pg/mL, 2.7% and 3.2%; at 355
pg/mL, 2.4% and 2.9%; at 1068 pg/mL, 1.9% and 2.6%; and at 4962 pg/mL, 1.8% and
2.3%, respectively.11
Global Left Ventricular Structure and Function
Baseline MRI of the heart was acquired using 1.5T magnetic resonance scanners. Short-axis
cine images were obtained with retrospective gating with a temporal resolution of ≤50 msec,
from above the mitral valve plane to the LV apex using fast gradient echo sequence. LV
structural parameters and LV ejection fraction were measured using standard commercially
available software (MASS 4.2, MEDIS, Leiden, The Netherlands), as previously described.7
In brief, the endocardial and epicardial myocardial borders were contoured using a
semiautomated method. The difference between the epicardial and endocardial areas for all
slices was multiplied by slice thickness and section gap and then multiplied by the specific
myocardial density (1.04 g/mL) to determine LV mass. The LV mass index was defined as
LV mass divided by body surface area.
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Clinical Follow-Up
A telephone interviewer contacted each participant (or representative) every 6 to 9 months to
inquire about interim hospital admissions, cardiovascular outpatient diagnoses, and deaths.
During follow-up, 5 participants were lost. Medical records were successfully obtained for
96% of the hospitalized cardiovascular events and 95% of the outpatient cardiovascular
diagnostic encounters. Two physicians reviewed all records for independent end point
classification and assignment of event dates. Reviewers classified HF as definite, probable,
or absent. Definite or probable HF required HF symptoms, such as shortness of breath or
edema. In addition to symptoms, classification of probable HF required diagnosis of HF by a
physician and a receipt for medical treatment for HF. Classification of definite HF required
the fulfillment of one or more additional criteria, such as evidence of pulmonary edema/
congestion by chest X-ray; dilated ventricle or poor LV systolic function (LV ejection
fraction <40%) by imaging methods; or evidence of LV diastolic dysfunction by
echocardiography.7 Myocardial infarction was diagnosed on the basis of a combination of
symptoms, electrocardiogram, and cardiac biomarker levels. Interim myocardial infarction
was defined as “newly diagnosed acute myocardial infarction during the follow period.” A
more detailed description of the MESA longitudinal follow-up methods is available at http://
www.mesa-nhlbi.org.
Statistical Analysis
Summary Analysis and Group Comparisons—Continuous variables were presented
as mean±SD or median (interquartile range) for variables with skewed distribution and
categorical variables were presented as percentages. Differences in clinical characteristics,
risk factors, MRI parameters, and incidence of HF by NT-proBNP quartiles were tested with
analysis of variance (continuous variables) or χ2 tests (categorical variables). Baseline
characteristics were stratified by sex. The Kruskal-Wallis test was used for variables with a
skewed distribution. Trends across quartiles were tested by 1-way analysis of variance using
polynomials equations for continuous variable and by Spearman correlation between
incidence number and quartile order from χ2 statistic in cross tab analysis. Because NT-
proBNP distributions were skewed, their log-transformed values were used for linear
regression analysis.
Survival Analysis With Continuous Log NT-proBNP—Cox Proportional Hazard
regression analysis was performed for the probability distribution of time to HF with log
NT-proBNP. The hazard ratio (HR) per 1 unit baseline log NT-proBNP was presented. The
association between log NT-proBNP and time to HF was analyzed using a series of models
with different covariate adjustments: Model 1 included age, sex, and ethnicity; Model 2
included the covariates of Model 1, plus diabetes, systolic blood pressure, current smoking,
low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, glomerular
filtration rate, and current medications (anti-hypertensive therapy and statins); Model 3
included the covariates of Model 2 plus LV mass index; and in Model 4, we added interim
myocardial infarction to the co-variates of Model 3. To explore the potential interactions of
NT-proBNP with sex and ethnicity on the incidence of HF, we evaluated the relationship
between log NT-proBNP and time to HF separately in each sex/ethnic group. In secondary
analyses, we incorporated interaction terms individually in multivariate analysis (log NT-
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proBNP × covariate) to test for the presence of effect modification by age, sex, and LV mass
index.
Survival Analysis With Categorical NT-proBNP and LV Mass Index—Categorical
variables were generated by dichotomizing NT-proBNP and LV mass index at the 75th
percentile. The Cox Proportional Hazard models for NT-proBNP quartiles and LV mass
index were investigated. The HR for the fourth NT-proBNP quartile was compared with a
group comprising the 3 lower quartiles in the successive models described earlier. Then, the
group of participants who underwent both NT-proBNP and cardiac MRI measurements were
cross-classified into 4 subgroups comprising those with NT-proBNP in the fourth quartile
(>112.5 pg/mL) or lower, and those with LV mass index above or below the 75th percentile
(86.78 g/m2). The HR of each subgroup for incident HF was compared after adjustment for
the covariates of Model 2.
Discrimination and Calibration Analysis—We tested and compared the
discrimination ability of NT-proBNP for HF beyond traditional risk factors and the LV mass
index via differences in the area under the curve (AUC) derived from receiver operating
characteristic curve analysis. AUCs were computed based on the predicted risk from Cox
hazards modeling and compared using a parametric method.12 We also evaluated the added
predictive ability of NT-proBNP as a new marker for the distributions of time to HF with
and without LV mass index using the newly developed Net Reclassification Improvement
(NRI) and Integrated Discrimination Improvement (IDI) calculations.13–16 As NRI and IDI
are defined by comparing the predicted probability of HF at a given time point and the
median follow-up time of MESA participants was ≈5.5 years, we calculated the AUCs and
the predicted probabilities of having HF within 6 years using Cox Proportional Hazard
models with and without log NT-proBNP for each MESA participant who had the observed
covariates. Details of the calculations were described in a supplemental appendix. Numerical
computations of the parameter estimates and test statistics were carried out using Splus 8
(TIBCO, Palo Alto, CA) software. For the calibration of predictive models, deciles of risk
were calculated for each model, after which the Hosmer-Lemeshow χ2 test was conducted
for each model. All statistical analyses were performed using SPSS (version 15.0, Chicago,
IL), STATA (version 9.0, College Station, TX), and Splus 8 (TIBCO, Palo Alto, CA)
software and 2-sided P-values <0.05 were considered to be significant.
Results
Baseline MESA Cohort Characteristics
Unadjusted baseline characteristics according to NT-proBNP quartiles are shown in Table 1.
Mean age was 62±10 years, and the median (interquartile range) NT-proBNP was 55 (24.0–
112.5) pg/mL. NT-proBNP levels in women were higher than in men (72.0 [37.5–138.8]
versus 38.5[15.7–81.4] pg/mL, P<0.001) and the log NT-proBNP correlated significantly
with age (r=0.465, P<0.001). Non-Hispanic whites had higher log NT-proBNP compared
with the other ethnic groups, even after adjustment for age, sex, glomerular filtration rate,
LV ejection fraction, and LV mass index (B= 0.378 higher in Non-Hispanic white, 95% CI,
0.15–1.04, P<0.001). Chinese and African-Americans had lower NT-proBNP than
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Hispanics. After adjustment for age, sex, and ethnicity log NT-proBNP was inversely
correlated with LV ejection fraction (B= −0.42, 95% CI −0.63 to −0.21, P<0.001), and
positively correlated with the LV mass index (B=3.09, 95% CI 2.66–3.52, P<0.001). Log
NT-proBNP remained inversely associated with glomerular filtration rate (B= −0.005,
−0.006 to −0.003, P<0.001) after adjustment for age, sex, and ethnicity.
Incident Heart Failure
The mean duration of follow-up was 5.5±1.1 years, during which 111 participants developed
symptomatic HF (3.6 per 1000 person-years), of which men had a higher incidence than
women (68 [4.6 per 1000 person-years] in men and 43 [2.7 per 1000 person-years] in
women). Chinese had a lower HF event rate compared with participants of other ethnicities
(6 [1.5 per 1000 person-years] Chinese, 25 [3.6 per 1000 person-years] Hispanics, 44 [3.6
per 1000 person-years] non-Hispanic whites, and 36 [5.0 per 1000 person-years] African-
Americans).
Association of Incident HF with Plasma NT-proBNP
Participants in the fourth quartile of NT-proBNP had a higher incidence of HF compared
with those in the lower quartiles (Figure 1). The HR of HF for those in the fourth NT-
proBNP quartile was 10.52 (95% CI 6.78–16.33, P<0.001), compared with those in the 3
lower quartiles. Similarly, as a continuous variable, each unit log NT-proBNP augmentation
was associated with a HR of 3.00 for HF (95% CI=2.59–3.42, P<0.001) in univariate
analysis. This relationship persisted both in continuous and categorical analyses after
adjustment for age, sex, and ethnicity (Model 1) and after further adjustment for systolic
blood pressure, diabetes mellitus, current smoking, LDL-cholesterol, HDL-cholesterol,
glomerular filtration rate, and current therapy with anti-hypertensives and/or statins (Model
2). Among MRI-derived variables, LV mass index was the best predictor for HF (LV mass
index, AUC=0.745, P<0.001; LV ejection fraction, AUC=0.632, P<0.001) in univariate
analysis. The relationship was modestly attenuated but remained significant when the LV
mass index was added in Model 3. Moreover, NT-proBNP was further attenuated but
remained significantly associated with a higher incidence of HF when interim myocardial
infarction was added in Model 4 (Table 2). Finally, the association of NT-proBNP with
incident HF did not vary by age, sex, or LV mass index based on incorporating interaction
terms in the analysis (Appendix 1). To investigate the confounding effect of body mass
index, we included body mass index and LV mass separately among Model 3 covariates
instead of LV mass index, and their relationship remained significant (HR 2.29, 95% CI
1.85–2.85, P<0.001 with logNT-proBNP; 6.61, 3.64–12.01, P<0.001 with fourth quartile of
NT-proBNP). In addition, when we added LV ejection fraction to the Model 3 covariates,
NT-proBNP remained significant (2.16, 1.74–2.70, P<0.001; 6.01, 3.32–10.88, P<0.001,
respectively).
Association of Incident HF with Plasma NT-proBNP by Sex and Ethnicity
Despite the fact that mean log NT-proBNP differed among ethnic groups, higher log NT-
proBNP was significantly related to incident HF within each ethnicity (Figure 1 and Table
2). However, among Chinese-Americans, the number of incident HF events was too small (6
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cases among 742 participants) for reliable analysis. Likewise, NT-proBNP significantly
predicted HF in participants of both sexes in adjusted models (data not shown).
Effects of NT-proBNP on Improvement in Model Performance
Comparison of C-statistics showed that NT-proBNP provided additive prognostic value
beyond traditional risk factors in Model 2 (C-index: 0.88 with versus 0.81 without NT-
proBNP, P<0.001) and in Model 3 (C-index: 0.89 with NT-proBNP versus 0.85 without
NT-proBNP, P=0.01) for predicting HF (Figure 2). The IDI showed significantly better
discrimination by the models that included NT-proBNP compared with Model 2 (IDI=0.088,
SE=0.017, z=5.062, P<0.001) and Model 3 (IDI=0.046, SE=0.014, z=3.327, P<0.001). The
NRIs after adding NT-proBNP to Model 2 was 0.370 (with <6%, 6–20% and >20%
category; SE=0.069, z-value=5.381, P<0.001) and 0.304 (with <3%, 3–10% and >10%
category; SE=0.069, z-value=4.415, P<0.001), respectively. NRIs after adding NT-proBNP
to Model 3 were 0.131 (SE=0.063, z-value=2.097, P=0.036 with <6%, 6–20% and >20%
category) and 0.175 (SE=0.074, z-value=2.347, P=0.019 with <3%, 3–10% and >10%
category), respectively (Table 3). Category-less NRI was 0.561 (model 3+NT-proBNP; 50
cases move-up and 25 cases move-down, 2495 noncases move-down and 1570 noncases
move-up; SE=0.117, z-value=4.813, P<0.001). The Hosmer-Lemeshow χ2 for the
calibration was 7.112 (P=0.525) in Model 3 without NT-proBNP and 10.55 (P=0.228) in
Model 3 with NT-proBNP.
Complementary Prognostic Value of NT-proBNP and the LV Mass Index
Although most cases of incident HF occurred among participants in the fourth quartile of
NT-proBNP, some HF events developed among those in the 3 lower quartiles (n=26), which
included most MESA participants (n=4199). In this group with lower values, the LV mass
index had greater predictive power (HR per 1 SD increment = 2.04, 1.36–3.06, P=0.001)
than NT-proBNP (HR per 1 SD increment = 1.46, 0.77–2.75, P=0.24 in model 3) before and
after adjustment for all covariates included in the previous analyses (Appendix 2). In
addition, among participants of both the highest quartile for NT-proBNP and for LV mass
index, the HR for incident HF was 33.63 compared with participants in the lower quartiles
for both variables after adjustment for Model 2 covariates (Table 4).
Discussion
The main finding of this study is that plasma NT-proBNP predicts incident HF in
asymptomatic individuals over and above established HF risk factors and LV hypertrophy
assessed as the LV mass index, as well as interim myocardial infarction. This relationship
was upheld in men and women and among individuals of different ethnicities. These
findings suggest that higher NT-proBNP is not only a mediator for other risk factors, but
may also function as an independent predictor of incident HF. Indeed, we demonstrate that
NT-proBNP levels are predictive of incident HF using C-statistics as well as discrimination
and reclassification analyses,13,14 which are currently considered as the standard methods
for evaluation of novel prognostic markers of cardiovascular risk.14,15 To confirm the
additive role of NT-proBNP, we also assessed NRI using different risk categories (<3%, 3–
10%, >10%; <6%, 6–20%, >20%) and also category-less NRI.16 In these additional
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analyses, significant discrimination was demonstrated after adding NT-proBNP to the
predictive models. These results support the concept that NT-proBNP measurements could
be included as part of the evaluation of patients suspected to be in the earliest states of HF
(stage B).17
Another potentially important result from this analysis is the finding that NT-proBNP values
differed by ethnicity. We previously demonstrated that incident HF18 and baseline LV
function19 were related to ethnicity in MESA, whereas similar relationships have been
demonstrated in other studies.20 This raises the possibility of ethnic differences in the
physiologic biomarker response to increased myocardial stress, which represents the
underlying cause of NT-proBNP production and release, and could be related to genetic
factors or exposure to unmeasured environmental confounders. However, regardless of the
different ethnic distributions of NT-proBNP, this study demonstrated that this biomarker
reliably predicted HF in <3 (Non-Hispanic whites, African-Americans, and Hispanics) of the
4 ethnic groups evaluated (among Chinese the power to test the hypothesis was limited).
These results support the generalizability of our findings to at least these 3 ethnicities.3
Although NT-proBNP has consistently been shown to be associated with clinically overt
HF, there is controversy as to whether higher NT-proBNP can predict HF among
asymptomatic individuals with lower levels of NT-proBNP or within the normal reference
range.3,6 In this study, 77% of the incident HF cases occurred among those in the top fourth
quartile of NT-proBNP (>112.5 pg/mL) for this population. Therefore, further risk
stratification is needed for individuals with lower levels of NT-proBNP, because most
individuals in an asymptomatic population fall into such category. Indeed, in the subgroup
with NT-proBNP below the fourth quartile, NT-proBNP was a weaker predictor of incident
HF than the LV mass index. This could be explained by a threshold effect for biomarker
release which may not be reached until the heart has exhausted its ability to carry out
hypertrophy and remodeling to maintain wall stress at low levels. Conversely, it could also
be secondary to NT-proBNP gene polymorphism,6,21–24 genetic predisposition, or the
possibility that HF in individuals with low baseline levels of NT-proBNP have a different
pathogenesis. In this subpopulation, increased LV mass, which reflects compensatory
remodeling in response to ventricular overload, was a better predictor of HF, and provided
additive prognostic information to NT-proBNP. Finally, by combining the LV mass index
with NT-proBNP, the overall predictive power was remarkably increased for both the lower
and the higher NT-proBNP subgroups, suggesting mutually additive prognostic power
between the imaging and biochemical markers. Therefore, although both NT-proBNP and
LV mass reflect responses to increased LV wall stress, their contribution to prognostication
might be mutually independent and complementary. Further studies are necessary to confirm
these findings.
This study has limitations that deserve discussion. First, the subgroup analyses, used to
determine the predictors for HF among MESA participants with lower NT-proBNP levels,
might have the well-known limitations of subgroup analysis in general.25 Second, it is
unclear whether the complementary risk prediction of NT-proBNP and structural LV indices
is secondary to measurement error as opposed to biological complementarity. Finally, the
number of incident HF events limited our ability to assess the effect of interactions fully.
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In conclusion, NT-proBNP provides additional predictive information for the future
development of HF, over and above traditional risk factors and the LV mass index in a
multiethnic asymptomatic population without baseline history of heart disease.
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Clinical Perspective
In this study of asymptomatic subjects from the Multi-Ethnic Study of Atherosclerosis, a
total of 5597 multiethnic participants without clinically apparent cardiovascular disease
underwent baseline measurement of N-terminal–pro B type natriuretic peptide, and were
followed for 5.5±1.1 years. Higher plasma N-terminal–pro B type natriuretic peptideat
baseline was associated with an increase in the risk of future incident heart failure even
after adjustment for traditional risk factors, left ventricular mass index and interim
myocardial infarction. This relationship held in men and women and among individuals
of different ethnic groups. N-terminal–pro B type natriuretic peptideprovided additive
prognostic value beyond both traditional risk factors and left ventricular mass index
(measured by cardiac magnetic resonance imaging, the most accurate methodology
currently available to assess left ventricular remodeling and hypertrophy) for predicting
incident heart failure. We conclude that N-terminal–pro B type natriuretic
peptideprovides additional predictive information for the future development of heart
failure, over and above traditional risk factors and the left ventricular mass index, in a
multiethnic asymptomatic population without baseline history of heart disease. These
data may have implications for screening strategies.
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Figure 1.
Kaplan-Meier curves of unadjusted cumulative hazard of incident heart failure according to
quartiles of N-terminal–pro B type natriuretic peptide in the entire study population (A) and
each ethnicity group (B, C, D). CHF indicates congestive heart failure.
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Figure 2.
Additive prognostic value of NT-proBNP beyond traditional risk factors and LV mass index.
A, NT-proBNP significantly improved receiver operating characteristic curve (ROC) area by
7% compared with traditional risk factors (covariates used in Model 2). B, NT-proBNP
significantly improved ROC area by 4% compared with traditional risk factors combined
with LVMI (Model 3). NT-proBNP indicates N-terminal–pro B type natriuretic peptide;
LVMI, left ventricular mass index AUC, area under the curve.
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Table 3
Reclassification of Heart Failure Risk With NT-proBNP
Model 3 Without NT-proBNP
Model 3 With NT-proBNP
<6% Risk 6–20% Risk >20% Risk Total no.
Cases (n=75*)
 <6% risk 29 (67.4%) 14 (32.6%) 0 43
 6–20% risk 4 (19.0%) 15 (71.4%) 2 (9.5%) 21
 >20% risk 0 2 (18.2%) 9 (81.8%) 11
 Total no. 33 31 11 75
Noncases (n=4065)
 <6% risk 3740 (97.4%) 97 (2.5%) 2 (0.1%) 3839
 6–20% risk 93 (47.2%) 93 (47.2%) 11 (5.6%) 197
 >20% risk 0 (0%) 9 (31.0%) 20 (69.0%) 29
 Total no. 3833 199 33 4065
<3% Risk 3–10% Risk >10% Risk Total no.
Cases (n=75)
 <3% risk 14 (51.9%) 12 (44.4%) 1 (3.7%) 27
 3–10% risk 6 (20.7%) 15 (51.7%) 8 (27.6%) 29
 >10% risk 0 4 (21.1%) 15 (78.9%) 19
 Total no. 20 31 24 75
Noncases (n=4065)
 <3% risk 3248 (95.4%) 151 (4.4%) 5 (0.1%) 3404
 3–10% risk 263 (47.3%) 254 (45.7%) 39 (7.0%) 556
 >10% risk 7 (6.7%) 39 (37.1%) 59 (56.2%) 105
 Total no. 3518 444 103 4065
Model 3 included age, sex, ethnicity, systolic blood pressure, use of anti-hypertensive treatment, presence of diabetes mellitus, current smoking,
LDL-cholesterol, HDL-cholesterol, statin use, glomerular filtration rate, and LV mass index. Sixteen cases moved upward and 6 cases downward;
110 controls upward and 102 controls downward with <6, 6–20, and >20% categories. The net classification improvement was estimated at 0.131
(P=0.036); 21 cases moved upward and 10 cases downward; 195 controls upward and 309 controls downward with <3%, 3–10%, >10% categories.
The net classification improvement was estimated at 0.175 (P=0.019). NT-proBNP indicates N-terminal–pro B type natriuretic peptide.
*Among 4163 participants who underwent both NT-proBNP and MRI, 76 cases of HF developed, and in 1 case risk probability could not be
calculated in this model because of missing data for a few covariables.
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Table 4
Hazard Ratio (95% CI) of Incident Heart Failure According to Elevated LV Mass Index
and NT-proBNP
NT-pro BNP in 4th Q LVMIin 4th Q Event no. /Sample Size (%) HR HR Adjusted
No No 8/2413 (0.3) 1 (reference) 1 (reference)
No Yes 11/769 (1.4) 4.35 (1.75–10.80) 3.28 (1.20–8.99)
Yes No 22/710 (3.1) 9.59 (4.27–21.55) 8.72 (3.50–21.70)
Yes Yes 35/271 (12.9) 46.03 (21.34–99.29) 33.63 (13.91–81.34)
112.5 pg/mL and 86.8 g/m2 are cut off values of 4th quartile LVMI and NT-proBNP, respectively. NT-proBNP indicates N-terminal–pro B type
natriuretic peptide; LV, left ventricle; HR, hazard ratio; LVMI, left ventricular mass index.
*Cox regression analysis and the results after adjustment of the covariates in Model 2.
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